Macquarie Initiation of coverage with Outperform
COMMENTARYMacquarie highlights the diversified nature of EML Payments with the company dealing in issue and management of physical and digital and prepaid stored-value products ranging from reloadable cards to traditional, single-store gift cards.
The broker expects the company to continue its strategy of diversifying away from the physical gift cards business and towards incentive programs and digital cards.
In FY21, about $19-$20bn of gross debit value (GDV) is expected to be processed with the broker forecasting an FY22 5-year compounded annual growth rate of 31% for revenue and 29% for gross profit.
Since about 45% of the GDV is generated mostly in December, the broker fears the lockdown measures in Europe, if extended over Christmas, present a downside risk to its FY21 forecasts.
Macquarie initiates coverage with an Outperform rating and a target price of $4.20.
FORECAST
Macquarie forecasts a full year FY21 dividend of 0.00 cents and EPS of 9.10 cents.
Macquarie forecasts a full year FY22 dividend of 0.00 cents and EPS of 15.20 cents.
- Forums
- ASX - By Stock
- EML
- Broker Valuations
Broker Valuations
-
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EML (ASX) to my watchlist
(20min delay)
|
|||||
Last
67.8¢ |
Change
-0.033(4.58%) |
Mkt cap ! $257.2M |
Open | High | Low | Value | Volume |
70.0¢ | 70.0¢ | 67.0¢ | $433.4K | 631.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 67010 | 67.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
68.0¢ | 33735 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 67010 | 0.675 |
9 | 123648 | 0.670 |
4 | 14300 | 0.665 |
12 | 61454 | 0.660 |
6 | 92741 | 0.655 |
Price($) | Vol. | No. |
---|---|---|
0.680 | 33735 | 15 |
0.685 | 13346 | 7 |
0.690 | 55444 | 7 |
0.695 | 14397 | 10 |
0.700 | 45386 | 4 |
Last trade - 12.05pm 13/11/2024 (20 minute delay) ? |
Featured News
EML (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online